Denise Myshko | Authors


Frontline Nivolumab Plus Ipilimumab Show Long-Term Benefit in mNSCLC

June 04, 2021

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Adjuvant Nivolumab Confers 30% Reduction in Disease Recurrence in MIUC

April 22, 2021

Findings from a A phase 3 trial evaluating adjuvant nivolumab following surgery versus placebo demonstrated an improvement in median disease-free survival in patients with muscle-invasive urothelial cancer, according to results from the CheckMate 274 trial presented at the 2021 Genitourinary Cancers Symposium.

Undetectable METex14 After Savolitinib Correlates With Positive Outcomes in NSCLC

April 12, 2021

After treatment with savolitinib, undetectability of MET Exon 14 in the circulating tumor DNA of patients with non‒small cell lung cancer was found to be associated with prolonged progression-free survival, and overall survival.